Forthcoming events

We are please to annouce the following related events.

Better Science, Better Health: New Healthcare Models
October 27-28th, Washington D.C.

There are multiple global initiatives currently investigating ways to improve and accelerate the way we bring needed new medicines to patients. How do we collaborate internationally to create better patient outcomes in the emerging world of precision medicine?


LIVE from EHFG: New Paths to Personalised Medicine: How Medicine’s Adaptive Pathways to Patients (MAPPs) and Breakthrough Designation will impact Patients
September 30th, Bad Gastein, Austria

Organised by European Alliance of Personalised Medicine (EAPM), European Federation of Pharmaceutical Industries and Associations (EFPIA) and Vital Transformation with the support of AstraZeneca. In a moderated discussion with experts, the audience and live participation from the public via the Twitter hashtag #EHFG2015, the panel investigated what the potential long-term implications of new models for personalised medicines are, and what their adoption means for regulators, payers, patients and society as a whole.


Advanced Pathways Workshop
June 30th, Brussels

This workshop aims to look into both the regulatory hurdles as well as discuss improvements in the market access based on evidence from recent years and situation in European countries.


Workshop: Adaptive Pathways; Opportunities, Challenges and Solutions For Health Technology Assessment?  (WS06)
June 13th, 13:30 – 17:00, Oslo

The development, regulatory and reimbursement system for medicines is in crisis with each stakeholder facing significant challenges. Following principles of systems engineering, the concept of an adaptive pathway has been proposed. Although often labelled as “adaptive licensing”, this mechanism looks at all components of the system. The HTAi ISGs on Conditional Coverage/Access with Evidence Development and HTA-Regulatory Interactions are exploring the opportunities and challenges this concept creates for HTA. Participants are invited to contribute through an interactive workshop that aims to identify the role of HTA in an adaptive system and to develop practical recommendations to overcoming some of the challenges of adaptive pathways.


MAPPs: Saving Time, Saving Lives
Luxembourg – June 4th, 2015 – 11:00 – 12:30 CET

Medicines Adaptive Pathways to Patients (MAPPs) will provide patients who have unmet medical needs more timely access to new therapies, and will do so within the current regulatory framework. The workshop will take place in the context of the EFPIA Annual Meetings, which are centred on the theme of big data for better health outcomes.

A full event report plus video is available here.

Featured speakers:

  • Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency (EMA)
  • Karin Van Baelen, Head Global Regulatory Affairs at Janssen, J&J
  • Luk Maes, Executive Director Regulatory Europe, Bristol-Myers Squibb
  • James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline, UK
  • Sue Forda, VP-Global Regulatory Affairs – International, Eli Lilly
  • Nathalie Seigneuret, Senior Scientific Project Manager, Innovative Medicines Initiative
  • Sarah Garner, Associate Director Science Policy and Research, NICE
  • Jeremy Haigh, EFPIA, moderator


STEPs in the Right Direction to a Brave New, Healthier & SMART Europe
Brussels – June 2-3, 2015

The European Alliance for Personalised Medicine look forward to welcoming you to our third annual conference, to be held at the University Foundation in Brussels on 2-3 June. The conference will focus on the fact that health policies need to recognise and tackle the inherent health system vulnerabilities faced, specifically, by smaller countries and in the regions of the larger ones. This is the SMART approach – Smaller Member states And Regions Together; and this will be further developed at the conference.


ISPOR 20th Annual International Meeting
May 16th – 20th, Philadelphia

Including the panel “Early Access to Medicines:  What’s in it for Payers?” Panelists:  Adam Heathfield (Pfizer), Mark Trusheim (MIT); Dan Ollendorf(ICER), Adrian Towse (Office of Health Economics, London).


Adaptive Designs in Clinical Trials
April 20th – 21st, London

This conference will review the drug development process and provide a detailed discussion of how adaptive designs are changing the development process. The main focus of the presentation will be to explore the role of adaptive sample sizing; in particular, why it is important to consider the need to reassess sample sizes during the course of a trial. It is designed for those looking to network and gain the latest knowledge from the academics, industry leaders and regulators.


Webinar: MAPPs – New Tools for Decision Making
April 14th, 15:00 – 15:00 CET

What is the current status of MAPPs in Europe and the US?


  • Luca Pani, Director General, Italian Medicines Agency
  • Gigi Hirsch, Executive Director, CBI and Program Director, NEWDIGS, MIT, USA
  • James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline, UK
  • Duane Schulthess, Managing Director, Vital Transformation (moderator)


DIA Europe 27th Annual EuroMeeting
April 13th – 15th, Paris

Including a panel discussion on Adaptive Licensing. Panelists: James Anderson (GSK), Susanna Del-Signore (Sanofi), Hans-Georg Eichler(EMA), Gigi Hirsch (MIT NEWDIGS).


MIT’s NEWDIGS Launches New Programme in Healthcare Data
January 2015, MIT

The inaugural meeting of the NEWDIGS Data Program was held in January 2015, and brought together international experts from academia, government, information technology, and the healthcare sector. A series of panel discussions focused on identifying the gaps and opportunities that might be addressed through better international cooperation in data system design and use. Through discussion, participants joined in formulating a research agenda with associated pilot programs to develop the tools, methods and policies needed to leverage real world evidence for better decision-making.


Farr Institute – ABPI Industry Forum 2014
December 16th, 2014
The Royal College of General Practitioners

The event will bring together academic and NHS health Informatics researchers from the Farr Institute and leaders in the use of real-world evidence from the Pharmaceutical Industry. The aim of the meeting is to help deepen and expand already established links which will facilitate the UK to attract investment from global pharmaceutical companies based on the UK’s world leading expertise in health informatics research.


WEBINAR: What are Medicine’s Adaptive Pathway’s to Patients (MAPPs)?
December 11th, 2pm – 3:30 PM CET

This webinar is by invitation only and open to the following participants:
All EFPIA, PhRMA, EBE and Vaccines Europe members

This webinar will update EFPIA members on Medicines Adaptive Pathways to Patients (MAPPs) and its potential impact on research, development, licensing, HTA, and pricing & reimbursement in relation to early patient access mechanisms.


MAPPs Taskforce Event, EFPIA – IMI – NEWDIGS, Better Science Better Health: A gathering of the world’s thought leaders in medicine’s adaptive pathways to patients (MAPPs).
20th & 21st October, London

We already have 150 registrations for our conference and we are still two months away. The hall capacity is 250, so please register if you would like to attend.


European Health Forum Gastein
1st October

Real World Patient Data


IMI2 Open Day
30 September, Brussels


EAPM Conference
9-10 September 2014, Brussels

Integrating Personalised Medicine into EU Strategy.